Eikon Therapeutics, Inc. EIKN
5.19 USD +0.03 (+0.68%)
As ofNov 18, 2026, 11:18 AM EST
5.02 Day range 5.38
4.95 52-week range 17.40
- YTD
- -65.43%
- 1 year
- -65.43%
News
benzinga.com Morgan Stanley Maintains Overweight on Eikon Therapeutics, Lowers Price Target to $30 Morgan Stanley analyst Sean Laaman maintains Eikon Therapeutics (NASDAQ:EIKN) with a Overweight and lowers the price target from $32 to $30.
benzinga.com Eikon Therapeutics Receives FDA Clearance To Proceed For Investigational New Drug Application To Evaluate EIK1006 For Treatment Of Advanced Metastatic Prostate Cancer; Expects Initial Clinical Data From Phase 1/2 Study In H2 2027 Eikon plans to initiate a Phase 1/2 study, ARGATE-001, to evaluate the safety, tolerability and preliminary efficacy of EIK1006 in participants with metastatic androgen-pathway-modulation-resistant…
globenewswire.com Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer MILLBRAE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…benzinga.com Eikon Therapeutics Q3 EPS $(1.59) Beats $(1.68) Estimate Eikon Therapeutics (NASDAQ:EIKN) reported quarterly losses of $(1.59) per share which beat the analyst consensus estimate of $(1.68) by 5.36 percent. This is a 93.44 percent increase over losses of…
globenewswire.com Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates MILLBRAE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings…benzinga.com Eikon Therapeutics Announces EIK1001 Plus Pembrolizumab And Chemotherapy In First-Line, Stage 4 Non-Small Cell Lung Cancer Demonstrates Durable Effect In Combination With Standard-Of-Care, With Tolerability Profile Supportive Of Systemic Administration In An Outpatient Setting EIK1001 Clinical Update:Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in…
benzinga.com Eikon Therapeutics Presents Initial And Updated Data For EIK1003 And Initial Data For EIK1004 And EIK1005 At ESMO 2026; Initial And Updated Cohort Data From Ongoing Phase 1/2 Study Of EIK1003 Continue To Support Potentially Differentiated Profile Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced…
